Oxford Ledge
Search
No licensed closing price on file for TRVI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:51 UTC.
Oxford Ledge is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release formulation of nalbuphine, for treating chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Haduvio works by acting as a kappa receptor agonist and mu receptor antagonist, targeting opioid receptors involved in the cough reflex. Nalbuphine has been used as an injectable pain medication for decades and is not scheduled as a controlled substance in the U.S.
Summarized from Trevi Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for TRVI and 5,000+ tickers.
Create a free account — keep TRVIGET /api/data?ticker=TRVI
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt